antiviral pill

Paxlovid offers 96% protection against hospitalization in high-risk patients who are incompletely vaccinated. It is also significantly protective in older adults who were vaccinated at least 6 months...

The FDA on Wednesday made it easier for clinicians to prescribe these antiviral drugs in cases where transmission is evident and the patient is at high risk of severe illness.

With monoclonal antibodies no longer effective against newer strains of SARS-CoV-2, the findings support prescribing the antiviral pill Paxlovid to eligible patients, doctors say.

Investigators plan to test whether the antiviral drug Paxlovid will relieve symptoms of the syndrome known as long COVID, also called post-acute sequelae of COVID-19.

Five medical societies have created a toolkit designed to help clinicians increase the effectiveness, accessibility and awareness of oral antiviral therapeutics and COVID-19 booster vaccines.

U.S. health officials have asked clinicians to help lessen the impact of an exceptional respiratory virus season on seniors and other vulnerable Americans.

Molnupiravir and Paxlovid appear to reduce the risk of death and hospital admission without increasing adverse events in patients with mild-to-moderate COVID-19, a sweeping review of studies has found.

Clinicians are writing 20,000 prescriptions for Paxlovid each day, helping to keep severe outcomes in check, the COVID-19 Response Coordinator said Wednesday.

New results confirm that Merck’s molnupiravir clears the virus quickly, lowering the risk of progression to severe illness in at-risk patients, researchers report.

The federal Long-Term Care Partner Program aims to quickly get time-sensitive COVID-19 treatments to facilities when an outbreak occurs. The first drug available via the portal will be molnupiravir, followed...